Tempus to buy cancer test maker Personalis for $1.5 billion - Reuters
Tempus to buy cancer test maker Personalis for $1.5 billion Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOeDdaUjUzN3pPOUFOZFZnRDQtelVrYUFKcDFGZUxMXzhxVFlQejhnSWJ2b2VkM2h0YnRfRXJ6Qm0tMFQ5eWNLZW4yRncwZXVvN2dZWFE4LS02WkRuS2JiblQ0U3VVSm9jaGs5TjdtNnhzLXFBMUNuYXlUd2o0OGxwd0kzaVc3UUZ5QUJBQmpfVFNOSkN3c0RKcktoekRBMFJENEFBa0JranFHSjJs?oc=5" target="_blank">Tempus to buy cancer test maker Personalis for $1.5 billion</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMSeligman Ventures doubles capital to $1 billion as AI boom revives hardware bets - Reuters
Seligman Ventures doubles capital to $1 billion as AI boom revives hardware bets Reuters
September 28, 2026 at 05:00 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AM